How Robust is the Cell & Gene Therapies Industry? Investment Funding and Commercial Returns

Thursday, January 18, 2024 at 3:00 PM to 4:00 PM · 1 hr. (US/Eastern)
Commercializing Future Therapies
Presentation
Theatre 5

Information

Chair

Peter Olagunju, Board of Directors, March Biosciences

3pm Presentation

Asthika Goonewardene, Managing Director, Truist Securities

Patrick Rivers, Managing Director & Head of Research, Aquilo Capital Management

3.15pm Presentation: Cell and Gene Therapy in 2024 – Surefire Strategies Regardless of Feast or Famine

  • How macro trends (e.g., 2030 patent cliff, CMS drug pricing negotiations) will impact CGT
  • Which funding, M&A, or clinical milestones are leading indicators for industry performance
  • What key facility/technology, process, and personnel investments yield ROI at the lowest risk in both bull and bear markets

John Lee, Vice President, Cell Therapy, SK Pharmteco

3.30pm Panel Discussion joined by

Gregory Fiore, Former Chief Executive Officer, Exacis Biotherapeutics

Deana Mohr, Chief Executive Officer & Co-Founder, MUVON Therapeutics

Modality
Cell & Gene Therapy
SK Pharmteco612SK Pharmteco is an innovative cell and gene therapy focused contract development and manufacturing organization located in the heart of “Cellicon Valley.” CBM’s integrated and comprehensive service offering provides a one-source solution to accelerate speed to market for advanced therapies. A client-driven approach coupled with a patient-centric culture delivers high quality and reliable process and analytical development, viral vector manufacturing, GMP testing, cell therapy bioprocessing, plasmid production, and cell banking services for a full product’s life cycle.

Documents & Links

  • John Lee, SK Pharmteco

    No Regret Strategies for Either Feast or Famine

  • Patrick Rivers & Asthika Goonewardene

    Investor Survey Analysis

Log in

See all the content and easy-to-use features by logging in or registering!